{
  "keyword": "Retatrutide Recomp Lean Mass",
  "generated_at": "2025-11-07T06:07:41.356400+00:00",
  "source": "seo_auto_pipeline",
  "articles_analyzed": 0,
  "articles": [],
  "combined_summary": "",
  "combined_insights": [],
  "outline": [
    "Introduction: Overview of Retatrutide Recomp Lean Mass",
    "What is Retatrutide Recomp Lean Mass?",
    "How it works (mechanisms)",
    "Evidence and research",
    "Dosing, safety, and side effects",
    "Practical use and protocols",
    "Conclusion and next steps"
  ],
  "keyword_suggestions": [],
  "research_brief": null,
  "curated_research": [],
  "knowledge_graph": {
    "focus_terms": [
      "glp-1 muscle loss",
      "lean",
      "lean mass",
      "mass",
      "recomp",
      "reta",
      "retatrutide"
    ],
    "nodes": [
      {
        "id": "peptide:retatrutide",
        "label": "Retatrutide",
        "type": "peptide",
        "source": "docs/peptides/cards/reta-card.md",
        "source_excerpt": "PEPTIDE CARD: RETATRUTIDE (LY3437943)\n\n\"Triple Agonist GLP-1/GIP/Glucagon for Maximum Fat Loss\u2014REQUIRES Maximum Support\"\n\n\u2554\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2557"
      },
      {
        "id": "content:dual-axis-recomp",
        "label": "Dual-Axis Recomposition",
        "type": "content",
        "source": "docs/content/dual-axis-recomp.md",
        "source_excerpt": "# Dual-Axis Recomposition Protocol\n\n## 1. Executive Overview\nDual-Axis Recomposition is a systems-level approach to body recomposition designed for athletes and high-control trainees who need simultaneous fat loss and muscle preservation (or gain). Instead of relying on simplistic caloric-deficit logic, the protocol synchronizes two daily metabolic axes:\n- **Daytime AMPK axis** \u2013 catabolic, fat-mobilizing, performance-focused."
      },
      {
        "id": "content:retatrutide-foundation",
        "label": "Retatrutide Metabolic Foundation",
        "type": "content",
        "source": "docs/content/retatrutide-metabolic-foundation.md",
        "source_excerpt": "# Retatrutide as Metabolic Foundation\n\n## Overview\n\nRetatrutide represents a fundamental approach to metabolic regulation, acting through three distinct receptor pathways:"
      }
    ],
    "neighbor_nodes": [
      {
        "id": "mech:UCP1",
        "label": "UCP-1",
        "type": "mechanism",
        "source": "docs/content/system_master/3-metabolic-axis.md:29",
        "source_excerpt": "---\n\n## 3.2 Retatrutide \u2014 The Command Signal\n\n**What it is:** Retatrutide activates three distinct receptors\u2014GLP-1, GIP, and glucagon\u2014that govern how we eat, burn, and store fuel."
      },
      {
        "id": "receptor:GIPR",
        "label": "GIP Receptor",
        "type": "receptor",
        "source": "docs/content/glp-1-comparison-specification.md:13",
        "source_excerpt": "| Feature | Semaglutide | Tirzepatide | Retatrutide |\n|---------|-------------|-------------|-------------|\n| **Receptor Targets** | GLP-1 only | GIP + GLP-1 | GIP + GLP-1 + Glucagon |\n| **Mechanism Focus** | Appetite suppression | Dual-action recomposition | Triple-action thermogenesis |\n| **Avg. Weight Loss** | 10\u201315% | 15\u201322% | 20\u201324% |"
      },
      {
        "id": "mech:AMPK",
        "label": "AMPK",
        "type": "mechanism",
        "source": "docs/content/system_master/2-mito-axis.md:152",
        "source_excerpt": "MOTS-C is a mitochondrial-encoded peptide\u2014a gene written inside mitochondrial DNA itself, not the cell nucleus.\nIt acts as a retrograde signal, informing the nucleus about mitochondrial status.\nWhen energy is low, MOTS-C activates AMPK, the enzyme that tells cells to stop storing and start burning.\n\nAMPK does several critical things:"
      },
      {
        "id": "axis:metabolic",
        "label": "Metabolic Axis",
        "type": "axis",
        "source": "docs/content/system_master/3-metabolic-axis.md:1",
        "source_excerpt": "# 3. The Metabolic Axis: Reprogramming Energy Flow\n\nFat loss and muscle preservation are not opposing goals\u2014they are competing signals."
      },
      {
        "id": "receptor:GLP1R",
        "label": "GLP-1 Receptor",
        "type": "receptor",
        "source": "docs/content/glp-1-comparison-specification.md:13",
        "source_excerpt": "| Feature | Semaglutide | Tirzepatide | Retatrutide |\n|---------|-------------|-------------|-------------|\n| **Receptor Targets** | GLP-1 only | GIP + GLP-1 | GIP + GLP-1 + Glucagon |\n| **Mechanism Focus** | Appetite suppression | Dual-action recomposition | Triple-action thermogenesis |\n| **Avg. Weight Loss** | 10\u201315% | 15\u201322% | 20\u201324% |"
      },
      {
        "id": "peptide:mots-c",
        "label": "MOTS-C",
        "type": "peptide",
        "source": "docs/peptides/cards/mots-c-card.md",
        "source_excerpt": "PEPTIDE CARD: MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c)\n\n\"Metabolic Flexibility Programming Through Exercise-Mimetic Signaling\"\n\n\u2554\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2557"
      },
      {
        "id": "receptor:GCGR",
        "label": "Glucagon Receptor",
        "type": "receptor",
        "source": "docs/content/glp-1-comparison-specification.md:13",
        "source_excerpt": "| Feature | Semaglutide | Tirzepatide | Retatrutide |\n|---------|-------------|-------------|-------------|\n| **Receptor Targets** | GLP-1 only | GIP + GLP-1 | GIP + GLP-1 + Glucagon |\n| **Mechanism Focus** | Appetite suppression | Dual-action recomposition | Triple-action thermogenesis |\n| **Avg. Weight Loss** | 10\u201315% | 15\u201322% | 20\u201324% |"
      },
      {
        "id": "mech:mTOR",
        "label": "mTOR",
        "type": "mechanism",
        "source": "docs/content/system_master/2-mito-axis.md:159",
        "source_excerpt": "2. Shifts fat metabolism toward oxidation instead of storage.\n3. Triggers mitochondrial biogenesis\u2014creating new mitochondria.\n4. Inhibits mTOR, the growth pathway that wastes energy during scarcity.\n\nIn effect, MOTS-C puts the cell in \u201csmart austerity\u201d mode\u2014improving efficiency, clearing damaged proteins, and stimulating mitochondrial renewal."
      },
      {
        "id": "peptide:tesamorelin",
        "label": "Tesamorelin",
        "type": "peptide",
        "source": "docs/peptides/cards/tesamorelin-card.md",
        "source_excerpt": "PEPTIDE CARD: TESAMORELIN\n\n\"Physiologic GH Restoration for Lean Mass Protection and Visceral Fat Reduction\"\n\n\u2554\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2557"
      },
      {
        "id": "peptide:l-carnitine",
        "label": "L-Carnitine",
        "type": "peptide",
        "source": "docs/peptides/cards/l-carnitine-card.md",
        "source_excerpt": "PEPTIDE CARD: L-CARNITINE\n\n\"The Mitochondrial Shuttle \u2014 Fat Oxidation & Cellular Energy Restoration\"\n\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550"
      },
      {
        "id": "protocol:ak-4week",
        "label": "AK 4-Week Protocol",
        "type": "protocol",
        "source": "docs/protocols/ak_4week_protocol_updated.md"
      },
      {
        "id": "peptide:aod-9604",
        "label": "AOD-9604",
        "type": "peptide",
        "source": "docs/peptides/cards/aod9604-card.md",
        "source_excerpt": "PEPTIDE CARD: AOD-9604 (GH Fragment 177-191)\n\n\"Modest Lipolytic Support for Fine-Tuning Optimized Cuts\"\n\n\u2554\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2557"
      },
      {
        "id": "peptide:nad",
        "label": "NAD+",
        "type": "peptide",
        "source": "docs/peptides/cards/nad-card.md",
        "source_excerpt": "PEPTIDE CARD: NAD+ (Nicotinamide Adenine Dinucleotide)\n\n\"The Power Supply - Cellular Energy Restoration\"\n\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550"
      }
    ],
    "relations": [
      {
        "source": "peptide:retatrutide",
        "target": "axis:metabolic",
        "relation": "part_of_axis",
        "evidence": "docs/content/glp-1-comparison-specification.md:1",
        "evidence_excerpt": "# Peptide Fox \u2014 GLP-1 Comparison Module (Specification)\n\nThis file defines the **GLP-1 Comparison Feature** for Peptide Fox \u2014 allowing users to visualize and interact with pharmacologic, mechanistic, and synergy-layer data for **Semaglutide**, **Tirzepatide**, and **Retatrutide**."
      },
      {
        "source": "peptide:retatrutide",
        "target": "peptide:nad",
        "relation": "synergizes_with",
        "evidence": "docs/synergies/integrated-systems-synergy-feedback-loops.md:1",
        "evidence_excerpt": "# Integrated Systems Synergy: Feedback Loops in Metabolic Optimization\n\n## Introduction: The Living Circuit"
      },
      {
        "source": "peptide:retatrutide",
        "target": "peptide:tesamorelin",
        "relation": "composes_stack_with",
        "evidence": "docs/synergies/peptide-synergy-diagram.md:1",
        "evidence_excerpt": "# Peptide Stack Synergy Map: Mechanistic Interactions and Cascades\n\n## Master Circadian Controller"
      },
      {
        "source": "peptide:retatrutide",
        "target": "peptide:l-carnitine",
        "relation": "composes_stack_with",
        "evidence": "docs/synergies/peptide-synergy-diagram.md:1",
        "evidence_excerpt": "# Peptide Stack Synergy Map: Mechanistic Interactions and Cascades\n\n## Master Circadian Controller"
      },
      {
        "source": "peptide:retatrutide",
        "target": "peptide:mots-c",
        "relation": "composes_stack_with",
        "evidence": "docs/synergies/peptide-synergy-diagram.md:1",
        "evidence_excerpt": "# Peptide Stack Synergy Map: Mechanistic Interactions and Cascades\n\n## Master Circadian Controller"
      },
      {
        "source": "peptide:retatrutide",
        "target": "peptide:aod-9604",
        "relation": "composes_stack_with",
        "evidence": "docs/synergies/peptide-synergy-diagram.md:1",
        "evidence_excerpt": "# Peptide Stack Synergy Map: Mechanistic Interactions and Cascades\n\n## Master Circadian Controller"
      },
      {
        "source": "protocol:ak-4week",
        "target": "peptide:retatrutide",
        "relation": "composes",
        "evidence": "docs/protocols/ak_4week_protocol_updated.md:235",
        "evidence_excerpt": null
      },
      {
        "source": "peptide:retatrutide",
        "target": "mech:AMPK",
        "relation": "raises",
        "evidence": "docs/content/system_master/3-metabolic-axis.md:22",
        "evidence_excerpt": "AOD-9604 \u2192 unlocks resistant fat stores\nL-CARNITINE \u2192 ensures liberated fat becomes fuel\nTESAMORELIN (\u00b1 IPAMORELIN) \u2192 protects and rebuilds structure\n```"
      },
      {
        "source": "peptide:retatrutide",
        "target": "mech:UCP1",
        "relation": "activates",
        "evidence": "docs/content/system_master/3-metabolic-axis.md:29",
        "evidence_excerpt": "---\n\n## 3.2 Retatrutide \u2014 The Command Signal\n\n**What it is:** Retatrutide activates three distinct receptors\u2014GLP-1, GIP, and glucagon\u2014that govern how we eat, burn, and store fuel."
      },
      {
        "source": "peptide:retatrutide",
        "target": "mech:mTOR",
        "relation": "inhibits",
        "evidence": "docs/content/system_master/3-metabolic-axis.md:22",
        "evidence_excerpt": "AOD-9604 \u2192 unlocks resistant fat stores\nL-CARNITINE \u2192 ensures liberated fat becomes fuel\nTESAMORELIN (\u00b1 IPAMORELIN) \u2192 protects and rebuilds structure\n```"
      },
      {
        "source": "peptide:retatrutide",
        "target": "receptor:GLP1R",
        "relation": "agonist_of",
        "evidence": "docs/content/retatrutide-metabolic-foundation.md:5",
        "evidence_excerpt": "## Overview\n\nRetatrutide represents a fundamental approach to metabolic regulation, acting through three distinct receptor pathways:\n\n### Key Receptor Pathways"
      },
      {
        "source": "peptide:retatrutide",
        "target": "receptor:GIPR",
        "relation": "agonist_of",
        "evidence": "docs/content/retatrutide-metabolic-foundation.md:11",
        "evidence_excerpt": "- Improves insulin sensitivity\n  - Slows gastric emptying\n  - Prevents post-meal blood sugar spikes\n  - Reduces fat storage drive"
      },
      {
        "source": "peptide:retatrutide",
        "target": "receptor:GCGR",
        "relation": "agonist_of",
        "evidence": "docs/content/retatrutide-metabolic-foundation.md:17",
        "evidence_excerpt": "- Enhances insulin release\n  - Influences nutrient partitioning between fat and muscle\n\n- **Glucagon Receptor**\n  - Promotes fat breakdown in liver"
      },
      {
        "source": "peptide:retatrutide",
        "target": "peptide:mots-c",
        "relation": "synergizes_with",
        "evidence": "docs/content/system_master/3-metabolic-axis.md:1",
        "evidence_excerpt": "# 3. The Metabolic Axis: Reprogramming Energy Flow\n\nFat loss and muscle preservation are not opposing goals\u2014they are competing signals."
      }
    ],
    "entity_types": {
      "peptide": 1,
      "content": 2
    },
    "semantic_entities": [
      {
        "entity": "Retatrutide",
        "type": "peptide",
        "id": "peptide:retatrutide",
        "seo_relevance": "primary"
      },
      {
        "entity": "Dual-Axis Recomposition",
        "type": "content",
        "id": "content:dual-axis-recomp",
        "seo_relevance": "primary"
      },
      {
        "entity": "Retatrutide Metabolic Foundation",
        "type": "content",
        "id": "content:retatrutide-foundation",
        "seo_relevance": "primary"
      }
    ],
    "internal_links": [
      {
        "anchor_text": "Retatrutide",
        "target": "docs/peptides/cards/reta-card.md",
        "type": "peptide"
      },
      {
        "anchor_text": "Dual-Axis Recomposition",
        "target": "docs/content/dual-axis-recomp.md",
        "type": "content"
      },
      {
        "anchor_text": "UCP-1",
        "target": "docs/content/system_master/3-metabolic-axis.md",
        "type": "mechanism"
      },
      {
        "anchor_text": "AMPK",
        "target": "docs/content/system_master/2-mito-axis.md",
        "type": "mechanism"
      },
      {
        "anchor_text": "Metabolic Axis",
        "target": "docs/content/system_master/3-metabolic-axis.md",
        "type": "axis"
      },
      {
        "anchor_text": "MOTS-C",
        "target": "docs/peptides/cards/mots-c-card.md",
        "type": "peptide"
      },
      {
        "anchor_text": "mTOR",
        "target": "docs/content/system_master/2-mito-axis.md",
        "type": "mechanism"
      },
      {
        "anchor_text": "Tesamorelin",
        "target": "docs/peptides/cards/tesamorelin-card.md",
        "type": "peptide"
      },
      {
        "anchor_text": "L-Carnitine",
        "target": "docs/peptides/cards/l-carnitine-card.md",
        "type": "peptide"
      },
      {
        "anchor_text": "AK 4-Week Protocol",
        "target": "docs/protocols/ak_4week_protocol_updated.md",
        "type": "protocol"
      }
    ],
    "content_clusters": {
      "part_of_axis": [
        {
          "source": "peptide:retatrutide",
          "target": "axis:metabolic"
        }
      ],
      "synergizes_with": [
        {
          "source": "peptide:retatrutide",
          "target": "peptide:nad"
        },
        {
          "source": "peptide:retatrutide",
          "target": "peptide:mots-c"
        }
      ],
      "composes_stack_with": [
        {
          "source": "peptide:retatrutide",
          "target": "peptide:tesamorelin"
        },
        {
          "source": "peptide:retatrutide",
          "target": "peptide:l-carnitine"
        },
        {
          "source": "peptide:retatrutide",
          "target": "peptide:mots-c"
        },
        {
          "source": "peptide:retatrutide",
          "target": "peptide:aod-9604"
        }
      ],
      "composes": [
        {
          "source": "protocol:ak-4week",
          "target": "peptide:retatrutide"
        }
      ],
      "raises": [
        {
          "source": "peptide:retatrutide",
          "target": "mech:AMPK"
        }
      ],
      "activates": [
        {
          "source": "peptide:retatrutide",
          "target": "mech:UCP1"
        }
      ],
      "inhibits": [
        {
          "source": "peptide:retatrutide",
          "target": "mech:mTOR"
        }
      ],
      "agonist_of": [
        {
          "source": "peptide:retatrutide",
          "target": "receptor:GLP1R"
        },
        {
          "source": "peptide:retatrutide",
          "target": "receptor:GIPR"
        },
        {
          "source": "peptide:retatrutide",
          "target": "receptor:GCGR"
        }
      ]
    },
    "notes": "Seed knowledge graph assembled from /docs (research \u2192 content \u2192 synergies \u2192 protocols). Iterative; add edges as content grows.",
    "generated_at": "2025-10-28T00:00:00Z"
  },
  "focus_terms": [
    "glp-1 muscle loss",
    "lean",
    "lean mass",
    "mass",
    "recomp",
    "reta",
    "retatrutide"
  ],
  "brief": {
    "primary_keyword": "Retatrutide Recomp Lean Mass",
    "secondary_keywords": [],
    "lsi_keywords": [
      "retatrutide",
      "dual-axis recomposition",
      "retatrutide metabolic foundation"
    ],
    "title_options": [
      "Retatrutide Recomp Lean Mass: Complete Evidence-Based Protocol",
      "How to Retatrutide Recomp Lean Mass: Step-by-Step Guide",
      "Retatrutide Recomp Lean Mass Protocol: Mechanisms, Implementation & Monitoring"
    ],
    "meta_description": "Retatrutide Recomp Lean Mass: Evidence-based protocol for body recomposition. Mechanisms, implementation, monitoring, and medical supervision required.",
    "angles_to_cover": [
      "Evidence-based implementation approach",
      "Medical supervision requirements",
      "Monitoring and safety parameters",
      "Individual response variability and adjustment protocols"
    ],
    "questions_to_answer": [
      "What is the evidence base for Retatrutide Recomp Lean Mass?",
      "How does Retatrutide Recomp Lean Mass work mechanistically?",
      "What monitoring and safety protocols are required for Retatrutide Recomp Lean Mass?",
      "Who is this protocol appropriate for, and who should avoid it?"
    ],
    "data_points_to_hunt": [
      "Body composition outcomes (fat mass vs lean mass changes)",
      "Performance metrics and strength retention data",
      "Metabolic markers and safety parameters"
    ],
    "storytelling_hooks": [],
    "structure": [
      {
        "heading": "Introduction: Overview of Retatrutide Recomp Lean Mass",
        "focus": "What & why; clinician oversight"
      },
      {
        "heading": "What is Retatrutide Recomp Lean Mass?",
        "focus": "Definitions & regulatory status"
      },
      {
        "heading": "How it works (mechanisms)",
        "focus": "Mechanisms & pathways"
      },
      {
        "heading": "Evidence and research",
        "focus": "Preclinical + small human studies"
      },
      {
        "heading": "Dosing, safety, and side effects",
        "focus": "Intranasal ranges; safety; disclaimers"
      },
      {
        "heading": "Practical use and protocols",
        "focus": "Adjunct use; tracking; supervision"
      },
      {
        "heading": "Conclusion and next steps",
        "focus": "Conservative positioning; next steps"
      }
    ],
    "source_material": [],
    "internal_links": [
      {
        "anchor_text": "Retatrutide",
        "target": "docs/peptides/cards/reta-card.md",
        "type": "peptide"
      },
      {
        "anchor_text": "Dual-Axis Recomposition",
        "target": "docs/content/dual-axis-recomp.md",
        "type": "content"
      },
      {
        "anchor_text": "UCP-1",
        "target": "docs/content/system_master/3-metabolic-axis.md",
        "type": "mechanism"
      },
      {
        "anchor_text": "AMPK",
        "target": "docs/content/system_master/2-mito-axis.md",
        "type": "mechanism"
      },
      {
        "anchor_text": "Metabolic Axis",
        "target": "docs/content/system_master/3-metabolic-axis.md",
        "type": "axis"
      },
      {
        "anchor_text": "MOTS-C",
        "target": "docs/peptides/cards/mots-c-card.md",
        "type": "peptide"
      },
      {
        "anchor_text": "mTOR",
        "target": "docs/content/system_master/2-mito-axis.md",
        "type": "mechanism"
      },
      {
        "anchor_text": "Tesamorelin",
        "target": "docs/peptides/cards/tesamorelin-card.md",
        "type": "peptide"
      },
      {
        "anchor_text": "L-Carnitine",
        "target": "docs/peptides/cards/l-carnitine-card.md",
        "type": "peptide"
      },
      {
        "anchor_text": "AK 4-Week Protocol",
        "target": "docs/protocols/ak_4week_protocol_updated.md",
        "type": "protocol"
      }
    ],
    "schema_recommendations": [
      "MedicalEntity/Drug for peptide mentions"
    ],
    "semantic_entities": [
      {
        "entity": "Retatrutide",
        "type": "peptide",
        "id": "peptide:retatrutide",
        "seo_relevance": "primary"
      },
      {
        "entity": "Dual-Axis Recomposition",
        "type": "content",
        "id": "content:dual-axis-recomp",
        "seo_relevance": "primary"
      },
      {
        "entity": "Retatrutide Metabolic Foundation",
        "type": "content",
        "id": "content:retatrutide-foundation",
        "seo_relevance": "primary"
      }
    ],
    "review_checklist": [
      "Validate all clinical claims against cited studies (add inline references).",
      "Include medical supervision / FDA status disclaimer for peptide use.",
      "Ensure ADHD guidance positions peptides as adjuncts, not replacements, unless evidence supports otherwise.",
      "Cross-check synergy and mechanism statements with knowledge graph evidence excerpts."
    ],
    "serp_intelligence": {
      "search_volume": 72000,
      "keyword_difficulty": 38,
      "competition_level": "medium",
      "traffic_potential": 79000,
      "recommend_targeting": true,
      "primary_intent": "informational",
      "cpc": 4.0
    },
    "serp_optimization_targets": [
      {
        "feature": "Featured Snippet / AI Overview",
        "strategy": "Answer main question concisely in 40-60 words at start of article",
        "priority": "high"
      },
      {
        "feature": "Video Results",
        "strategy": "Consider embedding relevant video content or creating video guide",
        "priority": "medium"
      },
      {
        "feature": "Image Pack",
        "strategy": "Include high-quality images with descriptive alt text and captions",
        "priority": "medium"
      }
    ],
    "related_keywords_to_include": [
      {
        "keyword": "compounded semaglutide vs semaglutide",
        "volume": 250,
        "difficulty": 53,
        "priority": "medium"
      },
      {
        "keyword": "can semaglutide kill you",
        "volume": 80,
        "difficulty": 64,
        "priority": "medium"
      },
      {
        "keyword": "weigh loss shots",
        "volume": 80,
        "difficulty": 59,
        "priority": "medium"
      },
      {
        "keyword": "gop1 weight loss",
        "volume": 70,
        "difficulty": 76,
        "priority": "medium"
      },
      {
        "keyword": "swmiglutide",
        "volume": 50,
        "difficulty": 85,
        "priority": "medium"
      },
      {
        "keyword": "semaglutide forms",
        "volume": 40,
        "difficulty": 72,
        "priority": "medium"
      },
      {
        "keyword": "glp-1 agonists pills",
        "volume": 20,
        "difficulty": 82,
        "priority": "medium"
      },
      {
        "keyword": "glp-1s approved for weight loss",
        "volume": 20,
        "difficulty": 68,
        "priority": "medium"
      },
      {
        "keyword": "ozempic for weight loss fda approval",
        "volume": 10,
        "difficulty": 69,
        "priority": "medium"
      }
    ]
  },
  "initial_draft": "---\ntitle: \"Retatrutide Recomp Lean Mass: Complete Evidence-Based Protocol\"\ndescription: \"Retatrutide Recomp Lean Mass: Evidence-based protocol for body recomposition. Mechanisms, implementation, monitoring, and medical supervision required.\"\ndate: \"2025-11-07\"\nlastmod: \"2025-11-07\"\nstatus: \"draft\"\ntags: ['Retatrutide', 'Recomp', 'Lean', 'Mass']\n---\n\n# Retatrutide Recomp Lean Mass: Complete Evidence-Based Protocol\n\n## Introduction: Overview of Retatrutide Recomp Lean Mass\n\nRetatrutide Recomp Lean Mass: Evidence-based protocol for body recomposition. Mechanisms, implementation, monitoring, and medical supervision required.\n\n*Focus:* What & why; clinician oversight\n\nThis section explores: What is the evidence base for Retatrutide Recomp Lean Mass?\n\n## What is Retatrutide Recomp Lean Mass?\n\n*Focus:* Definitions & regulatory status\n\nThis section explores: How does Retatrutide Recomp Lean Mass work mechanistically?\n\n## How it works (mechanisms)\n\n*Focus:* Mechanisms & pathways\n\nThis section explores: What monitoring and safety protocols are required for Retatrutide Recomp Lean Mass?\n\n## Evidence and research\n\n*Focus:* Preclinical + small human studies\n\nThis section explores: Who is this protocol appropriate for, and who should avoid it?\n\n## Dosing, safety, and side effects\n\n*Focus:* Intranasal ranges; safety; disclaimers\n\nKey perspective: Evidence-based implementation approach\n\n*Dosing information should be sourced from curated research documents and medical supervision*\n\n## Practical use and protocols\n\n*Focus:* Adjunct use; tracking; supervision\n\nKey perspective: Medical supervision requirements\n\n## Conclusion and next steps\n\n*Focus:* Conservative positioning; next steps\n\nKey perspective: Monitoring and safety parameters\n\n## References & Evidence\n\n- peptide:retatrutide \u2014[part_of_axis]\u2192 axis:metabolic\n  > # Peptide Fox \u2014 GLP-1 Comparison Module (Specification)\n\nThis file defines the **GLP-1 Comparison Feature** for Peptide Fox \u2014 allowing users to visualize and interact with pharmacologic, mechanistic, and synergy-layer data for **Semaglutide**, **Tirzepatide**, and **Retatrutide**.\n- peptide:retatrutide \u2014[synergizes_with]\u2192 peptide:nad\n  > # Integrated Systems Synergy: Feedback Loops in Metabolic Optimization\n\n## Introduction: The Living Circuit\n- peptide:retatrutide \u2014[composes_stack_with]\u2192 peptide:tesamorelin\n  > # Peptide Stack Synergy Map: Mechanistic Interactions and Cascades\n\n## Master Circadian Controller\n- peptide:retatrutide \u2014[composes_stack_with]\u2192 peptide:l-carnitine\n  > # Peptide Stack Synergy Map: Mechanistic Interactions and Cascades\n\n## Master Circadian Controller\n- peptide:retatrutide \u2014[composes_stack_with]\u2192 peptide:mots-c\n  > # Peptide Stack Synergy Map: Mechanistic Interactions and Cascades\n\n## Master Circadian Controller\n- peptide:retatrutide \u2014[composes_stack_with]\u2192 peptide:aod-9604\n  > # Peptide Stack Synergy Map: Mechanistic Interactions and Cascades\n\n## Master Circadian Controller\n\n_Disclaimer: Educational content only. Consult a licensed clinician before making changes to diagnosis or treatment._",
  "openai_models": {
    "article_summarizer": null,
    "research_brief": null
  },
  "anthropic_models": {
    "research_brief": null
  }
}